These small-cap healthcare stocks are definitely worth checking out this month.
News & Analysis: Geron
Geron announced an important regulatory win today.
Here's why shares of these drugmakers have a very slim chance to provide anything but losses.
GERN earnings call for the period ending June 30, 2019.
There wasn't much good news for the small biotech in Q2. But Geron continues to plug away with its imetelstat program.
Geron's stock has rebounded nicely in the first half of 2019.
Geron hints at a way forward for imetelstat in myelofibrosis, but the market isn't buying it.
These three cancer stocks have tremendous upside potential.
These three penny stocks have enormous upside potential, but they each come with a hefty dose of risk.
Warning: Small-cap stocks are risky, but the risk might be worth taking sometimes. Like with these three companies.